BioTheryX is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from cancer and inflammatory and immunological diseases through the discovery, development and commercialization of therapies that restore protein homeostasis through targeted protein degradation and modulation, and multi-kinase inhibition. We leverage our proprietary Protein Homeostatic Modulator technology platform and differentiated targeted protein degradation approach to design small molecules that regulate protein homeostasis. We believe our approach is applicable to a broad range of diseases, in particular those driven by protein targets that have been considered undruggable. Our initial programs are focused on oncology indications with high unmet medical need. For more information, please visit www.biotheryx.com and engage with us on LinkedIn.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.